Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Solid Tumor, Adult 1Sarcoma, Synovial 1Sarcoma 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Gliosarcoma 1Glioblastoma 1Dermatofibrosarcoma 1

Interventions

Doxorubicin 4pembrolizumab 3Specimen Handling 3toripalimab 2Ifosfamide 2Biopsy 2silmitasertib 1selinexor 1peposertib 1pemigatinib 1pazopanib 1palbociclib 1mirdametinib 1liposomal doxorubicin 1abemaciclib 1X-Rays 1Vincristine 1Trabectedin 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy 1Quality of Life 1Proton Therapy 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Irinotecan 1Injections 1Histamine H2 Antagonists 1Gemcitabine 1Famotidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Liposarcoma × peposertib × Clear all
NCT05711615 2026-05-15

Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma

National Cancer Institute (NCI)

Phase 1 Recruiting
30 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Sarcoma, Synovial, Dermatofibrosarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡